MRSA Drugs Market Overview
The MRSA Drugs Market is projected to reach USD 4130.46 Million by 2030 at 4.4% CAGR during the forecast period 2022-2030. Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen. This infection is generally associated with invasive procedures such as surgeries, intravenous tubing, and sometimes through the skin to skin contact. MRSA drugs are used to kill or restrain methicillin-resistant staphylococcus aureus infection.
The increase in the prevalence of MRSA infections and number of hospitals, growing awareness about a bacterial infection, and increase in immuno-compromised population are expected to enhance the market growth. However, the high cost of novel MRSA drugs and hospital readmissions reduction program is projected to curb the growth of the market.
Market Dynamics
MRSA drugs have been gaining significant growth in recent years owing to the rising awareness about MRSA infections. For instance, October is celebrated as world MRSA awareness month and November 18, is celebrated as antibiotic awareness day in Europe to raise awareness of antibiotic resistance and promote the judicious use of antibiotics. Thus, the growing awareness about the cause and treatment related to bacterial infection among the population led to an increased usage of MRSA drug market, which thereby provides a favorable scenario for the market to grow during the forecast period.
MRSA Drugs Market Share, by MRSA Type, 2016 & 2023
Source: MRFR Analysis
Segmentation
The MRSA drugs market, by drug class, has been segmented into sulfa drugs, tetracyclines, oxazolidinones, folate antagonists, lipopeptide, glycopeptide antibiotics, and others. Based on MRSA types, the MRSA drugs market has been categorized as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA). By disease indication, the market is divided into skin infections, bone and joint infections, and bacteremia, and animal infections. Based on end user, the MRSA Drugs market has been categorized as hospitals and clinics, research and academic institutes, and others.
North America MRSA Drugs Market Share, 2016 (%)
Source: MRFR Analysis
Regional Analysis
The MRSA drugs market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to hold the largest share of the MRSA drugs market. This is owing to the presence of key market players, well-developed healthcare infrastructure, in the US and Canada. Canada held 25% in North America MRSA Drugs market in 2016.
Europe holds the second position in MRSA drugs market due to the increasing research & development in the healthcare industry, availability of funds for research, rising cases of bacterial infection, and increasing adoption of novel drugs for the treatment of MRSA.
Asia-Pacific is projected to be the fastest-growing region in the global market due to the rapidly developing medical industry, the presence of a huge patient pool, and increasing expenditure in healthcare by the government. China held a share of 25.1% in the Asia-Pacific MRSA drugs market in 2016. The Middle East & Africa holds the least market share in the MRSA drugs market.
Key Players
The prominent players in the MRSA drugs market are Merck KGaA (UK), Olon (Italy), Allergan (Dublin, Ireland), Baxter (US), Theravance Biopharma (Theravance Biopharma), Pfizer (US), Mylan NV (US), and Novartis (Switzerland).
Some of the key strategies followed by players operating in the MRSA drugs market were innovation, product development, and acquisition & mergers.
- Americas showed high demand for the high-end MRSA drugs products due to broader market size and higher spending power.
- China is expected to be one of the top three fastest-growing markets for MRSA drugs shortly.
- Merck KGaA and Pfizer PLC are some of the prominent market players in the MRSA drugs market.
Market Segmentation
MRSA Drugs Market, by Drug Class
- Sulfa Drugs
- Tetracyclines
- Oxazolidinones
- Folate Antagonists
- Lipopeptide
- Glycopeptide Antibiotics
- Others
MRSA Drugs Market, by MRSA Type
- Hospital-Acquired (HA-MRSA)
- Community-Acquired (CA-MRSA)
MRSA Drugs Market, by Disease Indication
- Skin Infections
- Bone and Joint Infections
- Bacteremia
- Animal Infections
MRSA Drugs Market, by End User
- Hospitals and Clinics
- Research and Academic Institutes
- Others
MRSA Drugs Market, by Region
- Americas
- North America
- Latin America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Available Additional Customizations
-
Company Profiles of Other Key Players
- The Medicines Company
- Basilea Pharmaceutica Ltd
- Cellceutix
- Cempra
- CrystalGenomics
- Debiopharm
- Galapagos
- GSK
- MRSA Drugs Market, Industry Trends
Intended Audience
- Pharmaceutical companies
-
Contract research manufacturing organizations
- Research & development organizations
- Academic institutes
Report Attribute/Metric
|
Details
|
Market Size
|
USD 4130.46 Million
|
CAGR
|
4.4%
|
Base Year
|
2021
|
Forecast Period
|
2022-2030
|
Historical Data
|
2020
|
Forecast Units
|
Value (USD Million)
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
Segments Covered
|
Drug Class, MRSA Types, Disease Indication, End User
|
Geographies Covered
|
North America, Europe, Asia-Pacific, and Rest of the World (RoW)
|
Key Vendors
|
Merck KGaA (UK), Olon (Italy), Allergan (Dublin, Ireland), Baxter (US), Theravance Biopharma (Theravance Biopharma), Pfizer (US), Mylan NV (US), and Novartis (Switzerland).
|
Key Market Opportunities
|
New product launches and R&D Amongst major key Players
|
Key Market Drivers
|
Increase in the prevalence of MRSA infections and number of hospitals
Growing awareness about a bacterial infection
Increase in immuno-compromised population
|
MRSA Drugs Market Highlights:
Frequently Asked Questions (FAQ) :
MRSA drugs market projected to grow at approximately 4.4% CAGR during the assessment period (2022-2030).
The valuation of the global MRSA drugs market is estimated to increase to USD 4130.46 Million by the end of 2030.
Rising concerns and increasing government support to control MRSA infections are major tailwinds pushing the growth of the global MRSA drugs market.
North America holds the largest share in the global MRSA drugs market, followed by Europe and the Asia Pacific, respectively.
Olon, Merck KGaA, Theravance Biopharma, Allergan, Baxter, Pfizer, Novartis, and Mylan N.V, are some of the top players operating in the global MRSA drugs market.